Transthyretin Cardiac Amyloidosis
Conditions
Keywords
cardiology
Brief summary
Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly people. Nevertheless, research of TTR-CM is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. Therefore, the exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.
Detailed description
Not Provided
Interventions
PROCEDUREBony scintigraphy
Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
Sponsors
Pfizer
Poitiers University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient ≥ 60 years, hospitalised in cardiology wards of the Centre Hospitalier Universitaire of Poitiers * Left ventricle hypertrophy on echocardiography * Patient able to comply with study procedures * Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures * Patient having signed an informed consent after clear and fair information on the study
Exclusion criteria
* CardiacTransplant * Complex congenital cardiopathies * Know diagnosis of amylosis * Contra-indication to bony scintigraphy : hypersensitivity to sodium oxidronate or one of its excipients, or to one of the components of radiopharmaceutic marked product ; * Subject not able to comply with study procedures * Patients not benefiting from a Social Security scheme or not benefiting from it through a third party * Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, patients staying in a health or social establishment, adults under legal protection, and patients in emergency situation. * Women not menopausal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with a positive bone scintigraphy (perugini score> or = 2) in the absence of AL cardiac amyloidosis. | At Visit 2, one to four months after inclusion visit. | Percentage of patients with a positive bone scintigraphy (perugini score\> or = 2) in the absence of AL cardiac amyloidosis in patients over 60 years hospitalised in cardiology wards, with an hypertrophy of the left ventricle on transthoracic echocardiography (thickness of the left ventricle at the end of diastole \>12mm), whatever the possible cause of hypertrophy of the left ventricle (other potential cause not excluded), and without prior diagnosis of cardiac amylosis. |
Countries
France
Outcome results
None listed